Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cel-Sci Corporation Common Stock (NY:CVM)

0.2104 -0.0091 (-4.15%)
Official Closing Price Updated: 8:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cel-Sci Corporation Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Why CEL-SCI Stock Soared Today
The company attempted to clarify "confusion" related to its recent late-stage clinical results. 
Via The Motley Fool
CEL-SCI Corporation Issues Letter to Shareholders
From CEL-SCI Corporation
Via Business Wire
3 Biotechs to Avoid Like the Plague in July
Generally speaking, biotech is a pretty innovative industry -- with a few notable bad apples. 
Via The Motley Fool
Exposures COVID-19
Discussion of Results of CEL-SCI’s Phase 3 Trial Is Now Available
From CEL-SCI Corporation
Via Business Wire
Why CEL-SCI Shares Are Getting Hammered Today
CEL-SCI Corporation (NASDAQ:CVM) shares are trading lower b... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Before 10 a.m. ET on Friday, 43 companies set new 52-week lows. Points of Interest: Autohome (NYSE:ATHM) was the largest firm by market cap to set a new 52-week low... 
Via Benzinga
CEL-SCI to Conduct Investor Call Regarding Phase 3 Results Following Annual Shareholder Meeting on July 1, 2021
From CEL-SCI Corporation
Via Business Wire
72 Biggest Movers From Yesterday
Gainers Pop Culture Group Co., Ltd (NASDAQ: CPOP) shares jumped 405% to close at $30.30 on Wednesday after the company priced its IPO at $6 per share. Cuentas Inc. (NASDAQ: CUEN... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Will All End Well for This Popular Reddit Biotech?
Everything went the wrong way for Cel-Sci. 
Via The Motley Fool
51 Stocks Moving In Wednesday's Mid-Day Session
Gainers Cuentas Inc. (NASDAQ: CUEN) shares jumped 176.6% to $7.69. The stock spiked following a press release saying "WaveMax to Implement the World's First Shared Wifi6... 
Via Benzinga
Mid-Afternoon Market Update: Nasdaq Gains 100 Points; New Senior Investment Shares Spike Higher
Toward the end of trading Monday, the Dow traded down 0.49% to 34,266.49 while the NASDAQ rose 0.72% to 14,463.26. The S&P also rose, gaining 0.05% to 4,283.04. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
60 Biggest Movers From Yesterday
Gainers Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its... 
Via Benzinga
Nasdaq Hits Intraday Highs as Treasury Yields Retreat
The Dow Jones Industrial Average is 216 points lower at midday, erasing this morning's marginal gains amid growing pressures on energy and transportation stocks. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Mid-Day Market Update: Crude Oil Down Over 1%; Intellia Therapeutics Shares Jump
Midway through trading Monday, the Dow traded down 0.52% to 34,253.86 while the NASDAQ rose 0.72% to 14,463.56. The S&P also fell, dropping 0.01% to 4,280.50. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
44 Stocks Moving In Monday's Mid-Day Session
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy. Marin Software... 
Via Benzinga
Mid-Morning Market Update: Markets Mixed; Perion Network Boosts FY21 Outlook
Following the market opening Monday, the Dow traded down 0.30% to 34,329.01 while the NASDAQ rose 0.60% to 14,446.74. The S&P also rose, gaining 0.04% to 4,282.58. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
CEL-SCI's Immunotherapy Achieves Survival Benefit Of 14% Exceeding Pre-Defined 10% In Head & Cancer Patients
CEL-SCI Corporation (NYSE: CVM) has announced results from its Phase 3 study for its immunotherapy Multikine for advanced previously untreated squamous cell... 
Via Benzinga
CEL-SCI’s Multikine® Immunotherapy Produces Significant 14.1% 5-Year Survival Benefit (62.7% Vs 48.6%) in the Group Receiving Surgery Plus Radiotherapy in a Landmark Head and Neck Cancer Phase 3 Study
From CEL-SCI Corporation
Via Business Wire
24 Stocks Moving in Monday's Pre-Market Session
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) rose 28.9% to $114.49 in pre-market trading. Intellia Therapeutics and Regeneron Pharmaceuticals disclosed positive interim... 
Via Benzinga
CEL-SCI Corporation Invites Participants to Pre-Submit Questions for Annual Shareholder Meeting
From CEL-SCI Corporation
Via Business Wire
Cel-Sci Stock Shows Market Leadership With Jump To 81 RS Rating
Cel-Sci sees its Relative Strength Rating hit the 80-plus level. 
Via Investor's Business Daily
CEL-SCI Announces the Closing of $31.7 Million Bought Deal Offering
From CEL-SCI Corporation
Via Business Wire
28 Stocks Moving in Wednesday's Pre-Market Session
Gainers Aethlon Medical, Inc. (NASDAQ: AEMD) rose 72.4% to $3.81 in pre-market trading following Zacks article 'AEMD: First Ever In Vivo Removal Of COVID Virus From... 
Via Benzinga
62 Biggest Movers From Yesterday
Gainers Aethlon Medical, Inc. (NASDAQ: AEMD) shares surged 388.2% to close at $10.79 on Wednesday in reaction to Zacks Article 'AEMD: First Ever In Vivo Removal Of COVID... 
Via Benzinga
CEL-SCI Stock Drops After Raising $37.1M Via Secondary Equity Offering
CEL-SCI Corporation (NYSE: CVM) has increased the size of its previously announced capital raise offering to 1.4 million shares, up from 1 million shares, at... 
Via Benzinga
48 Stocks Moving In Wednesday's Mid-Day Session
Gainers Aethlon Medical, Inc. (NASDAQ: AEMD) shares jumped 371% to $10.41 in reaction to Zacks Article 'AEMD: First Ever In Vivo Removal Of COVID Virus From Bloodstream Of An... 
Via Benzinga
CEL-SCI Increases Previously Announced Bought Deal to $31.7 Million
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Announces Bought Deal Offering
From CEL-SCI Corporation
Via Business Wire
Can You Count on This Popular Reddit Cancer-Treatment Stock?
Big news is coming for CEL-SCI, and we don't know which way the stock will move. 
Via The Motley Fool
Cel-Sci Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
Cel-Sci stock saw an improvement to its Relative Strength Rating on Thursday, rising from 79 to 87, making the stock a potential watchlist candidate. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.